Date: April 15th-17th
Location: San Diego Convention Center, CA, USA, Booth 443
Join us at America’s most exciting biologics event, the Festival of Biologics in San Diego! We’re thrilled to invite you to Booth 443, where innovation meets excellence.
Explore how our cutting-edge microfluidic picodroplet technology platforms can transform your processes, from Cell Line Development to revolutionary advancements and beyond. Our team is eager to discuss how our solutions can accelerate your workflows, propelling your projects towards success.
Learn more about Picodroplets at our Poster Presentation - 16th April 18:10
Xin Liu will be presenting
Title:
Picodroplets for cell line development and antibody discovery: accelerating the discovery and development process
Description:
Antibody- based therapeutics have become the predominant class of new drugs developed in recent years, due to their high specificity, stability, adaptability and low side effects in the clinic (Kaplon et al, 2022). Despite their success, significant challenges and risks in the discovery and development of these therapeutics have resulted in low productivity and increased R&D costs (Bauer et al, 2023; Farid et al, 2020). Prolonged workflows, maintaining sterility, proof of monoclonality, identifying top clones and reducing human error are a few of these challenges affecting the Antibody Discovery (AbD) and Cell Line Development (CLD) work processes (Tejwani et al, 2021). Technologies allowing isolation of clones secreting high quality proteins at early stages of development are essential to accelerate therapeutic development.
While AbD through hybridoma system has contributed to a significant number of FDA-approved clinical antibodies, this process is lengthy and labor-intensive (Lu et al, 2020). A promising technique in isolating antigen-specific antibodies against infectious diseases is the single B cell isolation from human blood or lymphoid tissue. Despite the advantages offered by this method, it has had limited success in generating FDA-approved therapeutics due to the lack of reliable techniques in isolating antibodies from single B cell (Lu et al, 2020). Similar to AbD, the development of antibodies suffers from long workflow. Traditional CLD workflows typically take 6 to 12 months and are resource and labor-intensive, requiring identification of top clones from hundreds in the pool (Tejwani et al, 2021).
The Cyto-Mine® Single Cell Analysis and Monoclonality Assurance platform from Sphere Fluidics uses proprietary picodroplet technology, microfluidics and imaging in a single platform. Here we show how Cyto-Mine® tackles the issues discussed above during AbD and CLD processes, and significantly reduces time and cost. Furthermore, we will discuss future developments, whereby combining microfluidics with multi-lasers in Cyto-Mine® (Cyto-Mine® Quad) will allow a more sensitive platform for isolating rare and high producing cells of interest. Using the Cyto-Mine® Quad platform will enable isolation of cells based on their cell surface markers, viability and cell titer. Additionally, quality of secreted proteins can play a determining role on the isolation of top clones, accelerating lead selection. Cyto-Mine® Quad will further facilitate the setup of complex assays, such as combination of different cells types in a single droplet, required for binding assessment (e.g. for bispecifics), effector function and cytotoxic assays.
Location, Date & Time:
Poster #59, Poster Zone, 16th April, 18:10
